Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | AR | P10275 | 7/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | BRAF | P15056 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21568272 | 0.88 | BLM (0.47) | BLMHSD17B10 | |
| SCHEMBL23256590 | 0.87 | KCNQ3 (0.46) | BLMHSD17B10 | |
| SCHEMBL21568757 | 0.87 | BLM (0.56) | BLMHSD17B10 | |
| SCHEMBL21568374 | 0.85 | BLM (0.54) | BLMHSD17B10 | |
| SCHEMBL21568276 | 0.85 | BLM (0.56) | BLMHSD17B10 | |
| SCHEMBL21568078 | 0.84 | HSD17B10 (0.57) | BLMHSD17B10BRAFRAF1 | |
| SCHEMBL21568229 | 0.83 | BLM (0.54) | BLMHSD17B10 | |
| SCHEMBL23256576 | 0.81 | CSNK1D (0.63) | BLMHSD17B10KDRBRAFRAF1 | |
| SCHEMBL23256876 | 0.80 | MAPT (0.53) | BLMHSD17B10CA1CA2CA9 | |
| SCHEMBL23256888 | 0.79 | NSD2 (0.53) | BLMHSD17B10KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | VHL, TP53, NUDT1 | BLM 619/4885HSD17B10 4412/4885AR 3781/4885 |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | VHL, TP53, NUDT1 | BLM 692/4885HSD17B10 4512/4885AR 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.